Aa
A
A
Close
Avatar universal
ursodeoxycholic acid and hep c
One thing that HR told me when I recently went to see him was that ursodeoxycholic acid is important for hep c patients to take.

http://www.hivandhepatitis.com/hep_c/news/2007/070607_a.html


"Combination therapy with pegylated interferon (Pegasys or PegIntron) plus ribavirin has improved treatment for chronic hepatitis C, but many patients -- especially those with genotype 1 HCV -- fail to achieve sustained virological response. Such individuals could benefit from therapies that reduce liver inflammation and fibrosis, even if they do not produce virological suppression.

As reported in the June 25, 2007 advance online edition of Gut, researchers from the University of Tokyo assessed the effect of oral ursodeoxycholic acid (UDCA) on serum biomarkers in non-responders to prior interferon-based therapy. Chronic hepatitis C patients with elevated alanine aminotransferase (ALT) levels were randomly assigned to receive UDCA at doses of 150 mg/day (n = 199), 600 mg/day (n = 200), or 900 mg/day (n = 197) for 24 weeks. Changes in ALT, aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT) were measured.

Results

• ALT, AST, and GGT levels decreased at week 4, then remained constant for the remainder of the drug administration period.

• The median changes in the UDCA 150, 600, and 900 mg/day dose groups, respectively, were:

- ALT: -15.3%, -29.2%, and -36.2%;
- AST: -13.6%, -25.0%, and -29.8%%;
- GGT: -22.4%, -41.0%, and -50.0%.

• All 3 biomarkers decreased significantly less in the UDCA 150 mg/day arm compared with the 2 higher dose groups.

• While changes in ALT and AST did not differ between the 600 and 900 mg/day dose groups, GGT was significantly lower in the 900 mg/day group.

• In a subgroup analysis, ALT decreased significantly in the 900 mg/day group when baseline GGT exceeded 80 IU/L.

• Serum HCV RNA levels did not change in any group.

• Adverse side effects were reported by 19.1% of the patients, with no differences between the 3 dose groups.

Conclusion

In conclusion, the authors wrote, "A 600 mg/day UDCA dose was optimal to decrease ALT and AST levels in chronic hepatitis C patients. The 900 mg/day dose decreased GGT levels further, and may be preferable in patients with prevailing biliary injuries."
Cancel
2 Answers
Page 1 of 1
Avatar universal
Here's the full study:

http://gut.bmj.com/content/56/12/1747.full.pdf
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Avatar universal
"Adverse side effects were reported by 19.1% of the patients, with no differences between the 3 dose groups."

In the study they elucidate that diarhoea was the most common adverse reaction and there were no severe adverse reactions.

The study is pretty impressive.

But, after looking around, it also appears to be very expensive.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Your Answer
Avatar universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
Submit Answer
A
A
Recent Activity
317787 tn?1472134636
Blank
Dee1956 commented on stilltrying1965's status
2 hrs ago
317787 tn?1472134636
Blank
Dee1956 commented on Dee1956's status
23 hrs ago
317787 tn?1472134636
Blank
Dee1956 commented on Jade59's status
Aug 26
Blank
Weight Tracker
Track your weight over time
Start Tracking Now
Top Hepatitis Answerers
317787 tn?1472134636
Blank
DC
163305 tn?1333672171
Blank
Rural Mural, CA
446474 tn?1446351282
Blank
San Francisco, CA
Avatar universal
Blank
1747881 tn?1358189534
Blank
Greeley, CO
2059648 tn?1439770265
Blank
Hepatitis C Community Resources